%0 Journal Article
%T High
%A Ehab Abdelghany
%A Jalil Ur Rehman
%A Jamal Zekri
%A Mouhammed Kelta
%A Rawan Al-Saadi
%A Reyad Dada
%A Zahid Amin Khan
%J Tumori Journal
%@ 2038-2529
%D 2018
%R 10.5301/tj.5000591
%X High-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) is used to treat patients with relapsed Hodgkin¡¯s lymphoma. In this retrospective study we report our experience with patients who underwent HDCT and ASCT. All patients ¡Ý15 years old with relapsed/refractory Hodgkin¡¯s lymphoma who underwent HDCT and ASCT between June 2001 and December 2013 were included. Fifty-four patients were identified. Median age at transplant was 22 years (range 15-49 years); 26 were men and 28 were women. Forty-eight patients (89%) underwent HDCT and ASCT after achieving a radiological response to salvage chemotherapy. The rate of radiological complete response to salvage chemotherapy was 13% and reached 50% within 3 months of ASCT in assessable patients. After a median follow-up of 25 months, 31 patients (57%) were still alive with no evidence of relapse or progression. Median event-free survival (EFS) was 24 months (95% CI 8.7-39.3) and 3-year EFS was 56%. Median overall survival (OS) was not reached and 3-year OS was 82.5%. Bulky mediastinal disease at relapse, hemoglobin level, and number of salvage regimens did not significantly impact EFS in univariate and multivariate analyses. After transplantation there was a trend towards longer EFS (30 vs. 24 months; p = 0.36) in patients with a longer time from the end of first-line treatment until relapse (¡Ý12 vs. <12 months). The 100-day transplant-related mortality was 5.5%. HDCT and ASCT for relapsed/refractory Hodgkin¡¯s lymphoma is safe. Our findings are consistent with published phase III results. Longer follow-up is warranted
%K Autologous stem cell transplantation
%K High-dose chemotherapy
%K Hodgkin¡¯s lymphoma
%U https://journals.sagepub.com/doi/full/10.5301/tj.5000591